2-(6-Aminopyridin-3-yl)hexan-2-ol | 843643-06-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(6-Aminopyridin-3-yl)hexan-2-ol
• CAS: 843643-06-1
• 化学式: C₁₁H₁₈N₂O
• 分子量: 194.27
• InChiKey: AFXKKZHCLDBOLF-UHFFFAOYSA-N

物化性质

• 沸点：
  349.7±32.0 °C(Predicted)
• 密度：
  1.066±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  59.1
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders
  申请人：Chen L. Yuhpyng

  公开号：US20050107381A1

  公开（公告）日：2005-05-19

  The present invention relates to compounds of the Formula wherein R 1 , R 1a , R 1b , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , X, Y, W, U, Z, m and n are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. This invention also relates to pharmaceutical compositions and methods of treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.

  本发明涉及公式I的化合物，其中R1，R1a，R1b，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，R12，X，Y，W，U，Z，m和n如所定义。公式I的化合物具有抑制Aβ肽生成活性。本发明还涉及含有公式I化合物的制药组合物和治疗疾病的方法，例如神经退行性疾病，例如阿尔茨海默病，在哺乳动物中治疗。
• 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
  申请人：Pfizer Products Inc.

  公开号：EP1654260A2

  公开（公告）日：2006-05-10
• EP1654260A4
  申请人：——

  公开号：EP1654260A4

  公开（公告）日：2008-09-24
• [EN] 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] COMPOSES HETEROARYLE A 6 ELEMENTS POUR TRAITER DES TROUBLES NEURODEGENERATIFS
  申请人：PFIZER PROD INC

  公开号：WO2005011601A2

  公开（公告）日：2005-02-10

  The present invention relates to compounds of the Formula wherein R1, R1a, R1b, R2,, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, X, Y, W, U, Z, m and n are as definited. Compounds of the Formula (I) have activity inhibiting production of Aβ-peptide. This invention also relates to pharmatical compositions and methods of treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer’s disease, in a mammal comprising compounds of the Formula (I).